×
Select Language
mobile header
telelphone
language
Home > Doctors > Dr. Mangu S Bharadwaj
Dr. Mangu S Bharadwaj

Dr. Mangu S Bharadwaj american Oncology Hospitals

Dr. Mangu S Bharadwaj

Consultant - Nuclear Medicine

Book an Appointment
Share Profile share

Dr. Mangu S. Bharadwaj is of the best Nuclear Medicine Physicians in Hyderabad with around 7 years of experience, specialising in therapeutic nuclear medicine, theranostics, advanced oncologic molecular imaging and precision oncology. He currently serves as a Consultant – Nuclear Medicine at American Oncology Institute, Hyderabad.

His expertise includes PET/CT and SPECT/CT scans, targeted nuclear medicine therapies, radioiodine treatment, and other specialised treatments that use radioactive medicines to target cancer cells.

Dr. Bharadwaj has trained and worked at some of India's leading medical institutions, including AIIMS, New Delhi, JIPMER, Puducherry, and the Institute of Liver and Biliary Sciences, New Delhi. His areas of clinical interest include thyroid cancer, prostate cancer, neuroendocrine tumours, liver cancer and other cancers where nuclear medicine can support accurate diagnosis and targeted treatment.

He has also been actively involved in research and has several publications in national and international medical journals. His academic contributions have been recognised with the 2nd Best Oral Presentation Award at ANMPICON 2025 for his work on Y-90 radioembolization in liver cancer.

  • Assistant Professor – Nuclear Medicine, Institute of Liver and Biliary Sciences, New Delhi, 2025 - Present
  • Consultant – Nuclear Medicine, Institute of Liver and Biliary Sciences, New Delhi, 2023–2024
  • Consultant – Nuclear Medicine, Delhi Institute of Functional Imaging, New Delhi, 2022–2023
  • Senior Resident - Nuclear Medicine, AIIMS New Delhi, 2019-2021
  • MBBS, Rangaraya Medical College, Kakinada, 2008–2014
  • MD – Nuclear Medicine, JIPMER, Puducherry, 2016–2018
  • DM – Therapeutic Nuclear Medicine, AIIMS, New Delhi, 2019–2022
  • Level 1 Certification in Radiomolecular Precision Oncology, ICPO Academy for Theranostics, 2025
  • Certification Course in Clinical Oncology, 2025
  • PET-CT and SPECT-CT for accurate cancer diagnosis and monitoring
  • Targeted nuclear medicine treatments for cancer
  • Thyroid cancer diagnosis and radioiodine therapy
  • Prostate cancer imaging and targeted treatment
  • Neuroendocrine tumour diagnosis and treatment
  • Liver cancer imaging and targeted therapies, including Y-90 treatment
  • Bharadwaj MS, Ballal S, Bal C. Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events. J Clin Endocrinol Metab. 2024 Oct 15;109(11):e2120-e2130. doi: 10.1210/clinem/dgae024. PMID: 38214553.
  • Bharadwaj MS, Negi VS, Barathi D, Ponnusamy M. Utility of SPECT/CT in nontraumatic osteonecrosis: revisited with new insights from a prospective diagnostic study. Indian Journal of Nuclear Medicine. 2025;40:127-135.
  • Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, Tripathi M, Sahoo RK, Mangu BS, Tupalli A, Bal C. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid. 2022 Jan;32(1):65-77. doi: 10.1089/thy.2021.0412. Epub 2021 Dec 31. PMID: 34641705.
  • Jaleel J, Bharadwaj MS, Khangembam BC, Sulfiker S, Narayan ASJ. Diagnostic role of hepatobiliary scintigraphy in bile leak evaluation: a systematic review and meta-analysis. Asia Ocean Journal of Nuclear Medicine and Biology. 2026;14(1):15-25. doi:10.22038/aojnmb.2025.89502.1650.
  • Sahai P, Yadav HP, Choudhury A, Shasthry SM, Jindal A, Mall A, Mukund A, Patidar Y, Bharadwaj MS, Khangembam BC, Kumar G, Rastogi A, Pamecha V. Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis. BJR Open. 2025 Feb 18;7(1):tzaf002. doi: 10.1093/bjro/tzaf002. PMID: 40093581; PMCID: PMC11909637.
  • Sahai P, Mall A, Solanky AP, Jawahar V, Bharadwaj MS, Jaleel J, et al. Clinical outcomes with combination of stereotactic body radiation therapy in patients with hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 2025;21:1013-1025.
  • Ventrapragada N, Sahni S, Bharadwaj MS, Shamim SA, Rastogi S. Ripretinib in advanced gastrointestinal stromal tumors: a case series and literature review from a tertiary cancer center in India. Indian Journal of Medical and
  • Received the 2nd Position in Best paper in ANMPICON, Hyderabad 2025.
  • Society of Nuclear Medicine and Molecular Imaging (SNMMI)
  • Society of Nuclear Medicine, India (SNMI)
  • Association of Nuclear Medicine Physicians of India (ANMPI)
  • European Society for Medical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)

APMC/FMR/86545